The world cancer-treating drugs market is expected to grow at a CAGR of 6.6% in the second half of the forecast period. The market reached $102bn in 2016, dominated by the immunotherapy segment which held 44.1% share of the market.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 194-page report you will receive 110 tables and 101 figures – all unavailable elsewhere.
The 194-page report provides clear detailed insight into the world cancer-treating drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• World cancer-treating drugs market forecasts from 2017-2027
• This report also breaks down the revenue forecast for the world cancer-treating drugs market by its leading segments: – Immunotherapy – Chemotherapy – Targeted Therapy – Hormone Therapy
Each sector is analysed and revenue forecasts presented.
• This report provides individual revenue forecasts to 2027 for these regional and national markets: – North America: US, Canada, Mexico – South America: Brazil, Argentina, Paraguay, Brazil, Rest of South America – Europe: The UK, Germany, France, Spain, Italy, Rest of Europe – Asia-Pacific: China, Japan, India, Australia, Thailand, Rest of Asia-Pacific – Rest of World: Middle East, Africa, Other Countries
• This report discusses trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors (STEP) that influence the cancer-treating drugs market
• Our study discusses the selected leading companies that are the major players in the cancer-treating drugs market: – AstraZeneca – Merck & Co., Inc. (Merck) – Novartis – Amgen – Bristol-Myers Squibb (BMS) – GlaxoSmithKline (GSK) – Johnson & Johnson (J&J) – Roche – Eli Lilly – Celgene
The report provides overviews of the companies, financial information, product portfolio, pipeline products and recent developments.
Visiongain’s study is intended for anyone requiring commercial analyses for the world cancer-treating drugs market. You find data, trends and predictions.
Buy our report today World Cancer-Treating Drugs Market Forecast 2017-2027: Immunotherapy, Chemotherapy, Targeted Therapy, Hormone Therapy, Leading Drugs.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1 Report Overview 1.1 Global Cancer-Treating Drugs Overview 1.2 Research Methodology 1.2.1 Primary Research 1.2.2 Secondary Research 1.3 Market Evaluation & Forecasting Methodology 1.4 Global Cancer-Treating Drugs Market Segmentation 1.4.1 Global Top 25 Cancer Treating Drug Market 1.5 Overview of Findings 1.6 Why You Should Read This Report 1.7 How this report delivers? 1.8 Key Questions Answered by This Analytical Report 1.9 Frequently Asked Questions (FAQ) 1.10 Who is This Report For? 1.11 Associated Visiongain Reports 1.12 About Visiongain
2 Introduction to Cancer-Treating Drugs 2.1 The Physiology of Cancer – Causes and Effects 2.2 Uncontrolled Growth 2.3 Dedifferentiation 2.4 Invasiveness and Metastasis 2.5 Causes of Cancer 2.6 The Incidence and Prevalence of Cancer – Trends in the World 2.6.1 Incidence 2.6.2 Mortality 2.6.3 Survival – Improving Odds 2.7 The Developed World 2.7.1 The Developing World – More Must Be Done 2.8 Treating Tumours – How Can We Fight Back? 2.9 Chemotherapy – The Traditional Treatment 2.10 Hormone Therapies 2.11 Immunotherapy – A Magic Bullet? 2.11.1.1 Monoclonal Antibodies (mAbs) 2.11.1.2 Cancer Vaccines 2.11.1.3 Non-Specific Immunotherapies 2.11.1.4 Targeted Therapies 2.11.1.5 Differentiating Agents
3 Global Cancer-Treating Drug Market Forecast to 2027
4 Global Cancer Treating Drugs Market by Therapy: Market Forecast to 2027 4.1 Overview 4.2 Immunotherapy 4.3 Chemotherapy 4.4 Targeted Therapy 4.5 Hormone Therapy
6 Regional Cancer Treating Drugs Market Forecasts to 2027 6.1 Regional Cancer Treating Drugs Market Forecast 2017-2027 6.2 North American Cancer Treating Drugs Market Forecast 2017-2027 6.2.1 US Cancer Treating Drugs Market Forecast 2017-2027 6.2.2 Canada Cancer Treating Drugs Market Forecast 2017-2027 6.2.3 Mexico Cancer Treating Drugs Market Forecast 2017-2027 6.3 South American Cancer Treating Drugs Market Forecast 2017-2027 6.3.1 Brazil Cancer Treating Drugs Market Forecast 2017-2027 6.3.2 Argentina Cancer Treating Drugs Market Forecast 2017-2027 6.3.3 Paraguay Cancer Treating Drugs Market Forecast 2017-2027 6.3.4 Bolivia Cancer Treating Drugs Market Forecast 2017-2027 6.3.5 Rest of South America Cancer Treating Drugs Market Forecast 2017-2027 6.4 European Cancer Treating Drugs Market Forecast 2017-2027 6.4.1 France Cancer Treating Drugs Market Forecast 2017-2027 6.4.2 Germany Cancer Treating Drugs Market Forecast 2017-2027 6.4.3 UK Cancer Treating Drugs Market Forecast 2017-2027 6.4.4 Spain Cancer Treating Drugs Market Forecast 2017-2027 6.4.5 Italy Cancer Treating Drugs Market Forecast 2017-2027 6.4.6 Rest of Europe Cancer Treating Drugs Market Foons 9.1 The Top 25 Drugs in the Cancer Treatment Market 9.2 Immunotherapies – The Future of the Market 9.3 Patent Expiries and the Impact of Biosimilars 9.4 The US – Still the Largest National Market 9.5 China and Brazil Will Lead the Emerging Markets 9.6 Treatment – It’s Personal 9.7 The Anti-Cancer Drug Pipeline Remains Strong 9.8 Concluding Remarks
Appendices Visiongain Report Sales Order Form Appendix A About Visiongain Appendix B Visiongain report evaluation form
List of Tables Table 2.1 Cancer-Treating Agents: Chemotherapies and Hormone Therapies, 2017 Table 2.2 Cancer-Treating Agents: Immunotherapies, Targeted Therapies and Differentiating Agents, 2017 Table 3.1. Global Cancer-Treating Drugs Forecast ($bn, AGR%, CAGR%) 2017-2027 Table 4.1. Global Cancer Treating Drugs Market Forecast, by Therapy ($bn, AGR%, CAGR%) 2017-2027 Table 4.2. Global Immunotherapy Market for Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 4.3. Global Immunotherapy Market for Cancer Treating Drugs Market Forecast, by Geography, ($bn, AGR%, CAGR%) 2017-2027 Table 4.4. Global Chemotherapy Market for Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 4.5. Global Chemotherapy Market for Cancer Treating Drugs Market Forecast, by Geography ($bn, AGR%, CAGR%) 2017-2027 Table 4.6. Global Targeted Therapy Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 4.7. Global Targeted Therapy Cancer Treating Drugs Market Forecast, by Geography ($bn, AGR%, CAGR%) 2017-2027 Table 4.8. Global Hormone Therapy Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 4.9. Global Hormone Therapy Cancer Treating Drugs Market Forecast, by Geography ($bn, AGR%, CAGR%) 2017-2027 Table 5.1 Global Top 25 Cancer Treating Drugs Market, ($bn, AGR%, CAGR%) 2017-2027 Table 5.2. Global Avastin Revenue Forecast ($bn, AGR%, CAGR%), 2017-2027 Table 5.3. Global Herceptin Revenue Forecast ($bn, AGR%, CAGR%), 2017-2027 Table 5.4. Global Rituxan Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.5 Global Gleevec Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.6 Global Revlimid Revenue ($bn, AGR%, CAGR%),2017-2027 Table 5.7 Global Alimta Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.8 Global Velcade Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.9 Global Erbitux Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.10 Global Gardasil Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.11 Global Zytiga Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.12 Global Xeloda Revenue ($bn), Annual Growth (%) and CAGR (%),2017-2027 Table 5.13 Global Tarceva Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.14 Global Afinitor Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.15 Global Sprycel Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.16 Global Tasigna Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.17 Global Sutent Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.18 Global Nexavar Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.19 Global Xgeva Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.20 Global Zoladex Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.21 Global Yervoy Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.22 Global Vidaza Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.23 Global Treanda Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.24 Global Temodar Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.25 Global Faslodex Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.26 Global Abraxane Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 5.27 Global Others Revenue ($bn, AGR%, CAGR%), 2017-2027 Table 6.1. Global Cancer Treating Drugs Market, by Geography ($bn, AGR%, CAGR%) 2017-2027 Table 6.2. North America Cancer Treating Drugs Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2027 Table 6.3. US Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.4. Canada Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.5. Mexico Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.6. South America Cancer Treating Drugs Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2027 Table 6.7. Brazil Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.8. Argentina Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2016-2027 Table 6.9. Paraguay Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.10. Bolivia Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.11. Rest of South America Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.12. European Cancer Treating Drugs Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2027 Table 6.13. France Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.14 Germany Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.15 UK Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.16. Spain Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.17. Italy Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.18. Rest of European Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.19. Asia-Pacific Cancer Treating Drugs Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2027 Table 6.20. China Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.21. Japan Cancer Treating Drugs Market Forecast ($bn, AGR%, CAGR%) 2017-2027 Table 6.22. India Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.23. Australia Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.24. Thailand Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.25. Rest of Asia-Pacific Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.26. Rest of World Cancer Treating Drugs Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2027 Table 6.27. Middle East Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.28. Africa Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 6.29. Other Countries Cancer Treating Drugs Market Forecast, ($bn, AGR%, CAGR%) 2017-2027 Table 7.1 Strengths, Weaknesses, Opportunities and Threats in the Anti-Cancer Drugs Market, 2017 Table 7.2 Social, Technological, Economic and Political Analysis of the Anti-Cancer Drugs Market, 2017 Table 8.1 AstraZeneca Plc: Company Overview Table 8.2 AstraZeneca Plc: Pipeline Products Table 8.3 AstraZeneca Plc: Product Portfolio Table 8.4 AstraZeneca Plc: Recent Developments Table 8.5 Merck & Co. Inc.: Company Overview Table 8.6 Merck & Co. Ltd.: Pipeline Products Table 8.7 Merck & Co. Inc.: Product Portfolio Table 8.8 Merck & Co. Inc.: Recent Developments Table 8.9 Novartis AG: Company Overview Table 8.10 Novartis AG: Pipeline Products Table 8.11 Novartis AG: Product Portfolio Table 8.12 Novartis AG: Recent Developments Table 8.13 Amgen Inc.: Company Overview Table 8.14 Amgen Inc.: Pipeline Products Table 8.15 Amgen Inc.: Product Portfolio Table 8.16 Amgen Inc.: Recent Developments Table 8.17 Bristol-Myers Squibb: Company Overview Table 8.18 Bristol-Myers Squibb: Pipeline Products Table 8.19 Bristol-Myers Squibb : Product Portfolio Table 8.20 Bristol-Myers Squibb: Recent Developments Table 8.21 GlaxoSmithKline PLC: Company Overview Table 8.22 GlaxoSmithKline: Pipeline Products Table 8.23 GlaxoSmithKline PLC: Product Portfolio Table 8.24 GlaxoSmithKline PLC: Recent Developments Table 8.25 Johnson & Johnson: Company Overview Table 8.26 Johnson & Johnson: Pipeline Products Table 8.27 Johnson & Johnson: Product Portfolio Table 8.28 Johnson & Johnson: Recent Developments Table 8.29 F. Hoffmann-La Roche : Company Overview Table 8.30 F. Hoffmann-La Roche: Pipeline Products Table 8.31 F. Hoffmann-La Roche : Product Portfolio Table 8.32 F. Hoffmann-La Roche : Recent Developments Table 8.33 Eli Lilly and Company: Company Overview Table 8.34 F. Eli Lilly Company: Pipeline Products Table 8.35 Eli Lilly and Company : Product Portfolio Table 8.36 Eli Lilly and Company : Recent Developments Table 8.37 Celgene Corporation: Company Overview Table 8.38 Celgene Corporation: Pipeline Products Table 8.39 Celgene Corporation: Product Portfolio Table 8.40 Celgene Corporation : Recent Developments
List of Figures Figure 1.1 Anti-Cancer Market Segmentation, 2017 Figure 3.1 Cancer Treating Drugs Market, by Therapy, ($bn), 2017-2027 Figure 4.1 Cancer Treating Drugs Market, by Therapy, Market Share (%), 2016 Figure 4.2 Cancer Treating Drugs Market, by Therapy, Forecast ($bn) 2017-2027 Figure 4.3 Global Immunotherapy Market for Cancer Treating Drugs Market Forecast, by Geography, ($bn) 2017-2027 Figure 4.4 Global Chemotherapy Market for Cancer Treating Drugs Market Forecast, by Geography, ($bn) 2017-2027 Figure 4.5 Global Targeted Therapy Cancer Treating Drugs Market Forecast, by Geography, ($bn) 2017-2027 Figure 4.6 Global Hormone Therapy Cancer Treating Drugs Market Forecast, by Geography, ($bn) 2017-2027 Figure 5.1 Global Top 25 Cancer Treating Drugs, Market Share (%), 2016 Figure 5.2. Global Avastin Revenue Forecast, ($bn) 2017-2027 Figure 5.3. Global Herceptin Revenue Forecast, ($bn) 2017-2027 Figure 5.4. Global Rituxan Revenue Forecast, ($bn) 2017-2027 Figure 5.5. Global Gleevec Revenue Forecast, ($bn, AGR%, CAGR%), 2017-2027 Figure 5.6. Global Revlimid Revenue Forecast, ($bn) 2017-2027 Figure 5.7. Global Alimta Revenue Forecast, ($bn) 2017-2027 Figure 5.8. Global Velcade Revenue Forecast, ($bn) 2017-2027 Figure 5.9. Global Erbitux Revenue Forecast, ($bn) 2017-2027 Figure 5.10. Global Gardasil Revenue Forecast, ($bn) 2017-2027 Figure 5.11. Global Zytiga Revenue Forecast, ($bn) 2017-2027 Figure 5.12 Global Xeloda Revenue Forecast, ($bn, AGR%, CAGR%), 2017-2027 Figure 5.13. Global Tarceva Revenue Forecast, ($bn) 2017-2027 Figure 5.14. Global Afinitor Revenue Forecast, ($bn) 2017-2027 Figure 5.15. Global Sprycel Revenue Forecast, ($bn) 2017-2027 Figure 5.16. Global Tasigna Revenue Forecast, ($bn) 2017-2027 Figure 5.17. Global Sutent Revenue Forecast, ($bn) 2017-2027 Figure 5.18 Global Nexavar Revenue Forecast, ($bn) 2017-2027 Figure 5.19. Global Xgeva Revenue Forecast, ($bn) 2017-2027 Figure 5.20. Global Zoladex Revenue Forecast, ($bn) 2017-2027 Figure 5.21. Global Yervoy Revenue Forecast, ($bn) 2017-2027 Figure 5.22 Global Vidaza Revenue Forecast, ($bn) 2017-2027 Figure 5.23. Global Treanda Revenue Forecast, ($bn) 2017-2027 Figure 5.24. Global Temodar Revenue Forecast, ($bn) 2017-2027 Figure 5.25. Global Faslodex Revenue Forecast, ($bn) 2017-2027 Figure 5.26. Global Abraxane Revenue Forecast, ($bn) 2017-2027 Figure 5.27. Global Others Revenue Forecast, ($bn) 2017-2027 Figure 6.1. Global Cancer Treating Drugs Market, by Geography, ($bn) 2017-2027 Figure 6.2. Global Cancer Treating Drugs Market Forecast, by Geography, Market Share (%), 2016 Figure 6.3. North America Cancer Treating Drugs Market Forecast, by Country($bn) 2017-2027 Figure 6.4. North America Cancer Treating Drugs Market, by Country, Market Share (%), 2016 Figure 6.5. US Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.6. Estimation of Diagnosis of Canadian Cancer Immunotherapy Figure 6.7. Canada Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.8 Mexico Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.9 South America Cancer Treating Drugs Market Forecast, by Country($bn) 2017-2027 Figure 6.10. South America Cancer Treating Drugs Market, by Country, Market Share (%), 2016 Figure 6.11. Brazil Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.12. Argentina Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.13. Paraguay Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.14. Bolivia Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.15. Rest of South America Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.16. Europe Cancer Treating Drugs Market Forecast, by Country($bn) 2017-2027 Figure 6.17. Europe Cancer Treating Drugs Market, by Country, Market Share (%), 2016 Figure 6.18. France Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.19 Germany Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.20. UK Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.21. Spain Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.22. Italy Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.23. Rest of Europe Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.24. Asia-Pacific Cancer Treating Drugs Market Forecast, by Country($bn) 2017-2027 Figure 6.25. Asia-Pacific Cancer Treating Drugs Market, Market Share (%), 2016 Figure 6.26. Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.27. Japan Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.28. India Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.29. Australia Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.30. Thailand Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.31. Rest of Asia-Pacific Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.32. RoW Cancer Treating Drugs Market, by Country($bn) 2017-2027 Figure 6.33. Rest of World Cancer Treating Drugs Market, by Country, Market Share (%), 2016 Figure 6.34. Middle East Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.35. Africa Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 6.36. Other Countries Cancer Treating Drugs Market Forecast ($bn) 2017-2027 Figure 8.1 AstraZeneca Plc, Historical Revenue, ($billion), 2012-2016 Figure 8.2 AstraZeneca Plc, Product Segments Share (%), 2016 Figure 8.3 Merck & Co. Inc., Historical Revenue, ($Billion), 2012-2016 Figure 8.4 Merck & Co. Inc., Product Segments Share (%), 2016 Figure 8.5 Merck & Co. Inc., Geographical Presence Share (%), 2016 Figure 8.6 Novartis AG, Historical Revenue, ($billion), 2012-2016 Figure 8.7 Novartis AG, Product Segments Share (%), 2016 Figure 8.8 Novartis AG, Geographical Presence Share (%), 2016 Figure 8.9 Amgen Inc., Historical Revenue, ($billion), 2012-2016 Figure 8.10 Amgen Inc., Product Segments Share (%), 2016 Figure 8.11 Amgen Inc., Geographical Presence Share (%), 2016 Figure 8.12 Bristol-Myers Squibb, Revenue, ($billion), 2012-2016 Figure 8.13 Bristol-Myers Squibb, Product Segments Share (%), 2016 Figure 8.14 Bristol-Myers Squibb, Geographical Presence Share (%), 2016 Figure 8.15 GlaxoSmithKline PLC, Historical Revenue, ($billion), 2012-2016 Figure 8.16 GlaxoSmithKline PLC, Product Segments Share (%), 2016 Figure 8.17 GlaxoSmithKline PLC, Geographical Presence Share (%), 2016 Figure 8.18 Johnson & Johnson, Historical Revenue, ($Billion), 2012-2016 Figure 8.19 Johnson & Johnson, Product Segments Share (%), 2016 Figure 8.20 Johnson & Johnson, Geographical Presence Share (%), 2016 Figure 8.21 F. Hoffmann-La Roche, Historical Revenue, ($Billion), 2012-2016 Figure 8.22 F. Hoffmann-La Roche, Product Segments Share (%), 2016 Figure 8.23 F. Hoffmann-La Roche, Geographical Presence Share (%), 2016 Figure 8.24 Eli Lilly and Company, Historical Revenue, ($billion), 2012-2016 Figure 8.25 Eli Lilly and Company, Product Segments Share (%), 2016 Figure 8.26 Eli Lilly and Company, Geographical Presence Share (%), 2016 Figure 8.27 Celgene Corporation, Historical Revenue, ($billion), 2012-2016 Figure 9.1 Top 25 Anti-Cancer Drugs: Revenues ($bn), 2016 Figure 9.2 Global Cancer Drug Market by Geography: Revenues ($bn), 2017-2027 Figure 9.3 Global Cancer Drug Market by Therapy Type: Revenues ($bn), 2017-2027
AbbVie Active Biotech Advaxis Alchemia Allergan Amgen AmpImmune Argos Therapeutics ArQule AstraZeneca Barvarian Nordic Bayer Biothera BioXpress Therapeutics Boehringer Ingelheim Bristol-Myers Squibb Celator Pharmaceuticals Celgene Cephalon Clovis Oncology Cyclacel Daiichi Sankyo Dendreon Dr. Reddy’s Laboratories Eisai Eli Lilly EMA Sanofi EMD Serono Galena Biopharma Gilead GSK Heat Biologics Immatics Biotechnologies Infinity Pharmaceuticals Inovio Pharmaceuticals Janssen Jennerex Biotherapeutics Jiangsu Hengrui Medicine Johnson & Johnson MedImmune Merck & Co. Merck KGaA Merck Sharpe and Dohme Merrimack Newlink Novartis OncoGenex Onyx Orion OSi Pharmaceuticals Petrov Institute of Oncology Pfizer Pharmacyclics Progen Pharmaceuticals Puma Biotechnology Roche Spectrum Pharmaceuticals Spirogen Sun Pharma Sunesis Pharmaceuticals Syndax Takeda Telomedix TESARO Teva Pharmaceuticals Tracon Pharma Transgene United Therapeutics Vaccinogen Viventia Biotech Xbiotech
List of Organizations Mentioned in the Report American Cancer Society European Commission Food and Drug Administration (FDA) Japanese MHLW Massachusetts General Hospital National Cancer Institute National Comprehensive Cancer Network Rose Li and Associates
Download sample pages
Complete the form below to download your free sample pages for World Cancer-Treating Drugs Market Forecast 2017-2027
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
